Compare ESEA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESEA | VYGR |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 227.2M |
| IPO Year | 2005 | 2015 |
| Metric | ESEA | VYGR |
|---|---|---|
| Price | $71.12 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | $16.50 |
| AVG Volume (30 Days) | 47.9K | ★ 445.8K |
| Earning Date | 06-17-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $1.74 | $34.04 |
| Revenue Next Year | $1.07 | $7.92 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.40 | $2.65 |
| 52 Week High | $74.76 | $5.55 |
| Indicator | ESEA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 57.17 |
| Support Level | $51.63 | $3.71 |
| Resistance Level | $72.82 | $4.31 |
| Average True Range (ATR) | 3.04 | 0.19 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 52.42 | 82.91 |
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.